XTX Topco’s PharmaCyte Biotech PMCB Stock Holding History

XTX Topco’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$34.8K	Buy	52,362 +27,920	+114%	+$21.4K	﹤0.01%	3415
2025 Q4	$17.7K	Buy	+24,442	New	+$22K	﹤0.01%	3083

Other funds holding PMCB

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

XTX Topco's PMCB Position: Q1 2026 in Review

XTX Topco increased its PharmaCyte Biotech (PMCB) stake by 114% in Q1 2026, buying an estimated $21.4K and bringing the position to 52,362 shares worth $34.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3415.

XTX Topco first reported a position in PMCB in Q4 2025 and has held it in 2 quarters since. 32 funds tracked by Wall St. Rank hold PMCB as of Q1 2026.

XTX Topco held 52,362 shares of PharmaCyte Biotech worth $34.8K as of Q1 2026.
XTX Topco bought 27,920 PharmaCyte Biotech shares in Q1 2026, an estimated $21.4K.
PharmaCyte Biotech made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3415 holding.
XTX Topco first reported a position in PharmaCyte Biotech in Q4 2025 and has held it in 2 quarters since.
32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.